Trial Profile
A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 25 Jun 2017 Primary endpoint has been met. (Immune response to Pneumovax compared to immune response to Prevenar) as per result presented at the 22nd Congress of the European Haematology Association
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 05 Apr 2017 Based on the correspondance with investigator (Eva Kimby on 5 April 2017), Pfized had provided free prevenar and some economic support for monitoring to this trial.